X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (82) 82
humans (80) 80
oncology (73) 73
chemotherapy (40) 40
antineoplastic agents - adverse effects (38) 38
vomiting - chemically induced (38) 38
antiemetics - therapeutic use (37) 37
female (35) 35
vomiting - prevention & control (35) 35
cancer (34) 34
nausea (32) 32
nausea - chemically induced (31) 31
nausea - prevention & control (31) 31
middle aged (29) 29
aged (25) 25
adult (24) 24
health care sciences & services (24) 24
double-blind (23) 23
rehabilitation (23) 23
vomiting (23) 23
medicine & public health (22) 22
male (20) 20
moderately emetogenic chemotherapy (19) 19
prevention (19) 19
antiemetics - administration & dosage (17) 17
nursing (17) 17
pain medicine (17) 17
placebo-controlled trial (17) 17
rehabilitation medicine (17) 17
dexamethasone (16) 16
neoplasms - drug therapy (15) 15
practice guidelines as topic (15) 15
vomiting - drug therapy (15) 15
care and treatment (14) 14
nausea - drug therapy (14) 14
treatment outcome (14) 14
antiemetics (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
aprepitant (13) 13
cisplatin (13) 13
cisplatin-induced emesis (13) 13
drug administration schedule (12) 12
drug therapy (12) 12
hematology, oncology and palliative medicine (12) 12
research (12) 12
aged, 80 and over (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
drug therapy, combination (11) 11
gastrointestinal agents (11) 11
neurokinin-1 receptor antagonists (11) 11
ondansetron (11) 11
receptor antagonist (11) 11
double-blind method (10) 10
nursing management/nursing research (10) 10
survival (10) 10
antiemetics - adverse effects (9) 9
chemotherapy-induced nausea (9) 9
cisplatin - adverse effects (9) 9
prognosis (9) 9
cancer patients (8) 8
emesis (8) 8
morpholines - therapeutic use (8) 8
multiple cycles (8) 8
young adult (8) 8
breast-cancer (7) 7
cancer-chemotherapy (7) 7
clinical trials (7) 7
dexamethasone - therapeutic use (7) 7
induced nausea (7) 7
medical and health sciences (7) 7
medicin och hälsovetenskap (7) 7
nursing research (7) 7
ondansetron - therapeutic use (7) 7
ovarian cancer (7) 7
ovarian neoplasms - drug therapy (7) 7
palonosetron (7) 7
prospective studies (7) 7
radiotherapy (7) 7
retrospective studies (7) 7
serotonin antagonists (7) 7
abridged index medicus (6) 6
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
consensus (6) 6
delayed emesis (6) 6
drug administration routes (6) 6
high-dose metoclopramide (6) 6
medical research (6) 6
nausea - etiology (6) 6
palliative care (6) 6
patients (6) 6
pharmacology & pharmacy (6) 6
quality-of-life (6) 6
studies (6) 6
anthracyclines (5) 5
breast neoplasms - drug therapy (5) 5
carboplatin (5) 5
clinical trials as topic (5) 5
cyclophosphamide (5) 5
denmark - epidemiology (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 22, pp. 2154 - 2164
Among patients with platinum-sensitive, recurrent ovarian cancer, the use of niraparib, a PARP inhibitor, was associated with a significantly longer duration... 
TRIAL | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | BRCA MUTATION CARRIERS | NEGATIVE BREAST-CANCER | Humans | Middle Aged | Homologous Recombination | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Bone Marrow - drug effects | Double-Blind Method | Kaplan-Meier Estimate | Disease-Free Survival | Piperidines - therapeutic use | Piperidines - adverse effects | Adolescent | Aged | Indazoles - adverse effects | Neoplasm Staging | Indazoles - therapeutic use | Care and treatment | Adenosine diphosphate | Research | Diagnosis | Patients | Health aspects | Ovarian cancer | Thrombocytopenia | Adenosine | Inhibitor drugs | Toxicity | Homologous recombination | Clinical trials | Poly(ADP-ribose) polymerase | Breast cancer | Cancer therapies | Survival | Ribose | Platinum | Bone marrow | Mutation | Drug therapy | Health risk assessment | Tumors | Neutropenia | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 509 - 518
Journal Article
Expert Opinion on Drug Safety, ISSN 1474-0338, 10/2014, Volume 13, Issue 10, pp. 1407 - 1422
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 6, pp. 549 - 558
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 1/2019, Volume 27, Issue 1, pp. 265 - 273
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 1/2017, Volume 25, Issue 1, pp. 303 - 308
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2019, Volume 119, pp. 122 - 131
Age-related immune dysfunction (ARID) describes age-associated changes in immunity that may affect the efficacy of immunotherapy with checkpoint inhibitors. We... 
Pembrolizumab | Ipilimumab | Anti-CTLA4 | Malignant melanoma | Antibodies | Monoclonal | Anti-PD1 | Survival | Age | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2005, Volume 23, Issue 12, pp. 2822 - 2830
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 08/2019, Volume 27, Issue 8, pp. 2849 - 2856
IntroductionThe antipsychotic drug olanzapine is effective against chemotherapy-induced nausea and targets multiple receptors known to be involved in the... 
Advanced cancer | Nausea | Olanzapine | N/V | Vomiting | PALLIATIVE CARE | MANAGEMENT | CHEMOTHERAPY-INDUCED NAUSEA | PREVENTION | RELIEF | DELIRIUM | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | VERSION | REHABILITATION | EMESIS | Care and treatment | Gastrointestinal agents | Oncology, Experimental | Development and progression | Research | Aripiprazole | Cancer | Palliative care | Chemotherapy | Drug dosages
Journal Article